Lipid Emulsion, More Than Reversing Bupivacaine Cardiotoxicity: Potential Organ Protection

Negar Motayagheni1, Sheshanna Phan2, Ala Nozari3, Anthony Atala4

1Institute for Regenerative Medicine, Wake Forest School of Medicine , Winston Salem, NC, USA.
2Division of Molecular Medicine, Department of Anesthesiology’ UCLA David Geffen School of Medicine, Los Angeles, CA, USA.
3Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
4Institute for Regenerative Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA.

Abstract


Efforts to develop a treatment for bupivacaine cardiotoxicity led to the discovery that Intralipid, a popular brand of intravenous lipid emulsion, could be used not only as an effective treatment for anesthetic-induced cardiac arrest, but also as a means of reversing many other toxicities. Contradictory data exist regarding the mechanism of action of lipid emulsion, a combination of fatty acids traditionally used in parenteral nutrition. Some researchers attribute the effects to lipophilicity and the individual characteristics of the lipids, while other data demonstrate a direct empowering mechanism through cellular upstream and downstream pathways. Understanding the underlying mechanism of action of this safe source of calories may assist in the development of novel organ protective agents. In this review, some of the direct cardiac effects of lipid emulsion are briefly discussed.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.


J Pharm Pharm Sci, 20 (1): 329-331, 2017

Full Text:

PDF


DOI: http://dx.doi.org/10.18433/J30D2V